Huma s platform is ready to use, reducing the time and cost for other companies to bring regulated SaMD products to market, democratising digital health.
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 5,250,000 shares, a growth of 38.2% from the August 31st total of 3,800,000 shares. Based on an average trading volume of 670,100 shares, the short-interest ratio is […]